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Duchenne Muscular Dystrophy, the most common inherited X-linked genetic 
disease affecting 1 in 5000 boys, results from a dysfunctional dystrophin protein 
encoded by the DMD gene. Dystrophin interacts with protein complexes linking the 
extracellular matrix to the cytoskeleton of muscle fibers. Without dystrophin functioning 
properly, sarcolemmal membrane stabilization is compromised during the mechanical 
rigors involved with muscle contraction leading to progressive muscular dystrophy. 
Heregulin/neuregulin-1 (HRG), a member of the epidermal growth factor family has 
been shown to induce neuromuscular junction (NMJ) gene expression in vitro and 
improve skeletal muscle function in dystrophic mice. However, it is unclear if the HRG 
effects were due to proliferation, cell survival, differentiation, or stimulation of NMJ 
formation to improve excitation-contractile coupling. To identify a mechanism of action, 
HRG effects were investigated through in vitro and in vivo experiments: characterization 
of downstream signaling, observation of the effects on acetylcholine receptor clustering 
in vitro, and observation of NMJ morphology in vivo. In this study we show through 
Western blots and electrochemiluminesence assays that AKT and ERK were activated by 
HRG, but downstream effects were not clear. HRG decreased laminin-induced AChR 
clusters in a dose dependent manner in vitro, resulting in the possible reorganization of 
AChRs. In vivo, HRG was found to partially restore NMJ formation and increase axonal 
and muscle integration in the NMJ. This study provides evidence that a mechanism of 
action for the positive effects of HRG on the dystrophic phenotype in mdx mice are due 
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to a reorganization of AChRs and an improvement in NMJ formation, potentially 
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Duchenne muscular dystrophy 
Duchenne Muscular Dystrophy (DMD) was first described in 1861 by Edward 
Meryon followed by documentation in more detail by Guillaume-Benjamin-Amand 
Duchenne in 1868 (Emery & Emery, 1993). Duchenne reported a boy with calf muscle 
hypertrophy and evidence of a muscle disease though a histological examination of his 
muscle, which is known today as a muscle biopsy (Emery & Emery, 1993; Parent, 2005). 
The genetics of DMD were characterized in the 1980’s leading to the discovery that 
patients with DMD have an absence or dysfunction of the protein dystrophin in 1987 
(Davies et al., 1983; Hoffman, Brown, & Kunkel, 1987). 
  DMD, the most common muscular dystrophy and X-linked genetic disorder 
affecting 1 in 5000 boys, belongs in a class of non-congenital early childhood-onset 
muscular dystrophies, with Becker muscular dystrophy being a milder version of 
Duchenne seen later in childhood to adulthood (Mendell & Lloyd-Puryear, 2013; 
Mercuri & Muntoni, 2013).  Usually by the age of 2-3, but sometimes as late as 5 or 6 
years, patients with DMD will show symptoms of muscle weakness such as walking on 
toes, calf hypertrophy with a slow or awkward gait, exhibit fatigue, have trouble getting 
up from a sitting or lying position, and have frequent falls (Cyrulnik, Fee, De Vivo, 
Goldstein, & Hinton, 2007; Khurana & Davies, 2003; Sharma, Mynhier, & Miller, 1995).  
As a result of the progressive muscle weakness associated with the disease, children are 
usually late to walk and will use the Gowers’ maneuver to rise up off the floor, which is a 





patients while performing daily tasks such as playing with other children and climbing 
stairs due to progressive muscle weakness (Khurana & Davies, 2003). Eventually, muscle 
weakness is so severe that children around age 10 become permanently wheelchair-
bound (Voisin & de la Porte, 2004). About 30% of DMD patients have mental retardation 
and associated comorbidities such as autism and ADHD (Cyrulnik et al., 2008; Pane et 
al., 2012). Death usually occurs from cardiac or pulmonary failure in a patient’s second 
or third decades of life (Finder et al., 2004).   
DMD pathology is characterized by a repetitive cycle of muscle damage followed 
by muscle regeneration and tissue inflammation resulting in progressive muscle loss and 
the replacement of healthy tissue with fibro-fatty tissue (Figure 1 and 3) (Archer, Vargas, 
& Anderson, 2006; Khurana & Davies, 2003; Voisin & de la Porte, 2004). DMD patients 
experience a progressive loss of muscle mass and function in lower leg muscle (Cros, 
Harnden, Pellissier, & Serratrice, 1989). Hypertrophy is one of many dramatic 
phenotypes seen in early childhood and is characterized in DMD patients by the gain of 
mass in calf muscles due to the replacement of muscle with fibro-fatty tissue (Khurana 
& Davies, 2003; Verma, Anziska, & Cracco, 2010). Although symptoms can be treated to 
some extent and research has progressed over the past few decades, there is no cure.  
The most common treatment option is glucocorticoids, which can prolong ambulation 
but have consequential side effects such as obesity, short stature, cataracts and 
withdrawal (Manzur, Kuntzer, Pike, & Swan, 2004; Schara, Mortier, & Mortier, 2001). 
Glucocorticoids only slow the progression of the disease while slightly enhancing 





Joshi & Rajeshwari, 2009; Verma et al., 2010). Overall, DMD is an X-linked genetic 
disorder resulting in progressive muscle degeneration, cardiac dysfunction, respiratory 
deficiency, and early mortality. 
 
Figure 1: Pathophysiology of muscular dystrophy  
Adapted from Archer et al., 2006. 
Dystrophin 
Dystrophin, a 427-kDa protein, is encoded by the largest gene in the human 
genome (DMD) at 2.5Mb of genomic sequence that can code for 79 exons (J. M. Tinsley, 
Blake, Zuellig, & Davies, 1994; Wells, 2008). Dystrophin has an important structural role 
linking the dystrophin-associated glycoprotein complex at its C-terminus to F-actin at its 





Nowak & Davies, 2004). An example of the dystrophin-associated glycoprotein complex 
and associated proteins is shown below in Figure 2. A key feature of dystrophin that sets 
it apart from its homolog, utrophin, is the interaction with neuronal nitric oxide 
synthase (nNOS) at its C-terminus. In the absence of functional dystrophin, nNOS is 
located in the cytosol rather than near the sarcolemma and is unable to properly 
function during a muscle contraction resulting in insufficient blood supply, or ischemia, 
which can cause cell necrosis in skeletal and cardiac muscle cells (Heydemann & 
McNally, 2004; Sander et al., 2000). The dystrophin protein is also essential for 
neuromuscular junction (NMJ) architecture and folding of post-synaptic membranes, 
which contain acetylcholine receptors (AChR) (Shiao et al., 2004).  
DMD results from mutations in the dystrophin gene (DMD) located on the X 
chromosome (Xp21); mutations in the DMD gene are responsible for the missing or 
defective dystrophin protein (Davies et al., 1983; Ferlini et al., 2013; Saito et al., 1993; 
Tayeb, 2010). Large deletions in the DMD gene occur in 60% of DMD patients (Voisin & 
de la Porte, 2004). Point mutations, which usually introduce a premature stop codon, 
small deletions and duplications represent the other DMD mutations (Voisin & de la 
Porte, 2004). It is estimated that mothers who are carriers of DMD mutations are 
responsible for approximately two thirds of patients while the other patients are from 






            
Figure 2: Dystrophin-associated glycoprotein complex 
Dystrophin provides a crucial mechanical link between the extracellular matrix and 
intracellular cytoskeleton. (Davies & Nowak, 2006) 
 
DMD pathology 
When dystrophin is absent or truncated, a DMD patient’s muscles deteriorate 
and weaken (Wells, 2008). Muscle contraction can cause the weakened sarcolemma to 
become increasingly prone to rupture, leading to increased membrane permeability to 
Ca2+ (B J Petrof, 1993; Mallouk, Jacquemond, & Allard, 2000; Pato, Davis, Doughty, 
Bryant, & Gruenstein, 1983; Turner, Westwood, Regen, & Steinhardt, 1988). The 
elevated Ca2+ levels are speculated to contribute to an increased activation of Ca2+-
dependent proteases that could affect cell function/viability and early deterioration of 





Duport, Guillou, & Raymond, 1995; Ohlendiec, 2002). In addition, altered calcium levels 
affect Ca2+-gated K⁺-channels, membrane potential and activation potential for muscle 
contraction (Turner et al., 1988). Compromised sarcolemma initiates muscle repair, as 
the plasma membrane is a vital barrier and essential for cell survival (Han, Rader, Levy, 
Bansal, & Campbell, 2011; Head, 1993; Mallouk et al., 2000). During muscle injury 
mitochondria migrate to the area of injury and block off damaged tissue, while muscle 
stem cells (satellite cells) proliferate at the site, fuse to form new tubes, fuse with 
damaged muscle fibers and restore muscle fiber integrity (Wallace & McNally, 2009). In 
patients with DMD, damaged muscle attempts to compensate for tissue injury with help 
from satellite cell proliferation, myoblast differentiation and repair; yet, endeavors at 
repair are met with partial success and inflammation from macrophage infiltration and 
fibrosis are often a result of tissue damage (Nowak & Davies, 2004). Due to the 
excessive regeneration of skeletal muscle in patients with DMD, satellite stem cell 
populations quickly become depleted preventing muscle repair and results in dystrophic 
muscle (Jejurikar & Kuzon, 2003). An example of DMD muscle pathology is shown in 






Figure 3:  DMD muscle pathology 
H&E staining of normal (A) and DMD (B-F) muscle tissue showing the consequences due 
to the absence of dystrophin resulting in: inflammation (B), degeneration (C), necrosis 
(D), regeneration (E), and fibrosis (F) (BioMarin internal figure, courtesy of Sean Bell). 
 
Dystrophin-deficiency is also responsible for NMJ fragmentation on regenerating 
muscle fibers (Kong & Anderson, 1999). Since dystrophin is required for AChR 
organization, the absence of dystrophin contributes to the reduction and distribution of 
AChR clustering over time (Personius & Sawyer, 2005).  Nerve-dependent mechanisms 
are also responsible for the spatial organization of AChRs (Marques, Pertille, Carvalho, & 





DMD is lethal. DMD patients are caught in a vicious cycle of progressive muscle 
damage and tissue repair. Muscle stem cells can only compensate for so long due to 
extensive depletion before necrosis occurs initiating a fatty, fibrous-like, tissue 
replacement. Regardless of improvements in medical technology and prolongation of 
survival of DMD patients within in the past decades, DMD invariably results in death 
usually by cardiac or respiratory failure (Passamano et al., 2012).  
mdx, a mouse DMD model 
To better understand DMD disease pathology, animal models of dystrophin-
deficiency are used, such as the mdx mouse (Bulfield, Siller, Wight, & Moore, 1984; 
Ryder-Cook et al., 1988). The mdx mouse carries a premature stop codon at exon 23 
preventing the production of a functional dystrophin protein (Im et al., 1996). Mdx mice 
have a slightly shorter lifespan, reduced cardiac function, and a progressive loss and/or 
damage to skeletal muscle (Nowak & Davies, 2004). The disease phenotype in mdx mice 
is much less severe when compared to humans. Mdx mice show less fibrosis, a near 
normal lifespan and are completely mobile when compared to boys with DMD 
(Chamberlain, Metzger, Reyes, Townsend, & Faulkner, 2007). It is believed the mild mdx 
phenotype is due to increased compensatory utrophin expression and higher muscle 
regeneration capacity in mice (Chamberlain et al., 2007; Pons, Robert, Marini, & Leger, 
1994; Weir, Morgan, & Davies, 2004).   
As evidence of the effect of the higher regeneration capacity of mice compared 





proliferative capacity was generated. Dystrophin- and telomerase-deficient mice were 
generated and shown to have significantly impaired proliferation potential of muscle 
satellite cells, and a more sever dystrophic phenotype representative of human disease, 
including much earlier mortality (Mourkioti et al., 2013; Sacco et al., 2010). 
Unfortunately, due to the lack of the availability of this model and the challenging 
nature of developing dystrophin- and telomerase-deficient mice, only mdx mice were 
available for this study.   
The therapeutic potential of Heregulin β-1 
HRG, a trophic factor encoded by the Neuregulin-1 gene (NRG1), is one protein 
of potentially fifteen splice variants (Falls, 2003; Holmes et al., 1992) (Figure 4). During 
embryogenesis, HRG is necessary and involved in glial growth, cardiac development, and 
acts as a neuronal cell differentiation factor (Britsch, 2007; Vartanian, Fischbach, & 
Miller, 1999) . Mice that lack HRG die in utero due to cardiac defects (Barros et al., 2009; 
Ueda et al., 2005). Although HRG is normally associated with neuronal tissue, HRG is 
also endogenously expressed in muscle cells and vascular endothelium (Britsch, 2007). 
However, mice lacking muscle-derived HRG live post partum, which confirms that HRG is 
not essential for muscle development (Jaworski & Burden, 2006). Not only does HRG 
have developmental roles, but HRG has positive effects on muscle function and provides 
protection from cerebral and cardiac ischemic injury in adults (Britsch, 2007; Fang et al., 






Figure 4: NRG1 gene and gene products  
The NRG1 gene and several potential isoforms. A) The location and genomic structure of 
NRG1. B) NRG1 splice varients and resulting protein products. The 71 amino acid 
fragment of HRG β-1 encoding only the EGF domain used for this study is outlined in 
blue. (Adapted from Falls, 2003.) 
HRG signaling via ErbB2  
HRG initiates various functions through the activation of the kinase ErbB2 and its 
downstream signaling (Earp, Calvo, & Sartor, 2003; Plowman et al., 1993). HRG binds to 
the extracellular domain of ErbB3/ErbB4, which then heterodimerizes with ErbB2 to 
initiate signaling by phosphorylation of the intracellular C-terminal domain as a result of 
the heterodimeric receptor tyrosine kinase (RTK) formation between ErbB2/3 (or 





ErbB2/3 is activated by HRG, AKT (Protein Kinase B), and ERK 1/2 (Extracellular Receptor 
Kinase / Mitogen-activated Protein Kinase) can be downstream signaling targets (Falls, 
2003; Roskoski, 2012). HRG signaling is not a straight line. HRG-associated signaling 
pathways and potential cellular effects are shown in Figure 5 (Newbern & Birchmeier, 
2010). 
 
Figure 5: Heregulin (NRG1) signaling pathways and cellular effects  
(Newbern & Birchmeier, 2010).  
 
HRG and neuromuscular junctions 
 NMJs are important for the transmission of signals from nerves to muscle and 
require Acetylcholine receptor (AChR) clustering for accurate signaling (Ferraro, 
Molinari, & Berghella, 2012). One of many neurotransmitters, acetylcholine (ACh), is 





to orchestrate the appropriate muscle contraction (Fagerlund & Eriksson, 2009; Sudhof, 
2004; Vartanian et al., 1999). When ACh is released from the motor neuron, it binds to 
the AChR at a 2:1 ratio inducing the depolarization of the postsynaptic membrane and 
stimulates muscle contraction (Fagerlund & Eriksson, 2009).  
NMJs have a high degree of plasticity and are constantly remodeled due to 
muscle contraction, making each NMJ unique (Pratt et al., 2013). Following muscle 
injury, the axon branches will regenerate to reform synapses (Pratt et al., 2013). NMJs in 
mdx mice are shown to be particular susceptible to damage and may contribute to 
dystrophic muscle (Pratt et al., 2013). NMJs are malformed in DMD patients as well as in 
mdx mice and demonstrate a discontinuous bouton formation as shown in Figure 6. In 
mdx mice, axonal branching is increased and bundles of AChRs are dispersed resulting in 
NMJ fragmentation (Pratt et al., 2013). 
 In the peripheral nervous system, Schwann cells form a necessary protective 
myelin sheath that promotes faster nerve impulses and while residing at the NMJ, help 
to stabilize the interaction with muscle through adherence to the basement membrane 
(Corfas, Velardez, Ko, Ratner, & Peles, 2004). In a recent publication, HRG signaling 
response in Schwann cells restored thickness of the myelin sheath and induced 
hypermyelination of damaged nerves (Stassart et al., 2013). HRG signaling via ErbB2 is 
known to regulate AchR gene transcription and other proteins in NMJs (Bezakova & 








Figure 6: WT and mdx NMJs 
NMJs were identified by labeling AChRs with α-bungarotoxin-alexa fluor 555 and imaged 
by confocal microscopy.  Wild type (WT) mouse (Left) showing a continuous “pretzel –
like” NMJ formation and an mdx mouse (Right) showing a discontinuous bouton NMJ 
formation distributed in islands due to the absence of the dystrophin protein.  
 
HRG may affect NMJ formation though ERK activation. Through in vitro 
experiments, HRG activated ERK in C2C12 myoblasts and myotubes resulted in the up-
regulation of NMJ genes which can be beneficial for NMJ formation and possibly 
translate to the restoration muscle function (Handschin et al., 2007; Tansey, Chu, & 
Merlie, 1996). HRG effects on NMJ formation may improve the excitation-contraction 
coupling, an action potential resulting in a contraction, which is defective in DMD 
patients due to poorly formed NMJs (Schertzer, van der Poel, Shavlakadze, Grounds, & 
Lynch, 2008). Signaling from the HRG-ERK-NMJ gene up-regulation pathway at the NMJ 





                                          
Figure 7: HRG signaling at the NMJ 
HRG is shown to regulate transcription of AChR and other NMJ genes though its 
receptor kinase, ErBb2/3 (adapted from Bezakova G & Ruegg M, 2003). 
Heregulin and utrophin 
Heregulin β-1 (HRG) has shown therapeutic qualities in the mdx mouse as well as 
an effect on utrophin levels in vitro (Basu et al., 2007; Gramolini et al., 1999; Krag et al., 
2004). Utrophin, an autosomal homolog of dystrophin, forms a similar utrophin-
associated glycoprotein complex in the neuromuscular junction and has an 80% 
homology to dystrophin (Marshall & Crosbie-Watson, 2013; Voisin & de la Porte, 2004). 
Utrophin up-regulation is a popular therapeutic theory for the substitution of 
dystrophin. Utrophin has been shown to be up-regulated by HRG in C2C12 cells and in 
mdx mice (Basu et al., 2007; Handschin et al., 2007; Krag et al., 2004). It was observed 
that the transgenic induction of utrophin improved the dystrophic phenotype in mdx 





to have improved strength, decreased inflammation, and reduced muscle damage; this 
improvement was postulated to be mediated by an increase in utrophin (Krag et al., 
2004).  
One of the limitations in the Krag study was the small number of mice studied. 
The mdx mouse phenotype is highly variable. Only five mice were treated and it has 
been shown by Nagaraju and Wilmann that a minimum of 10 mice are needed to 
significantly power an mdx therapeutic study (Nagaraju & Willmann, 2009). It was 
proposed by Krag that a two-fold induction of utrophin was sufficient to ameliorate the 
dystrophic phenotype. Results from experiments performed at BioMarin have shown 2-
fold differences in utrophin protein and mRNA levels between individual mdx mice; such 
individual variation raises questions about the significance of such a small change in 
utrophin levels (S. Bell, personal communication).  Although no clear mechanism of 
action was identified, HRG had beneficial therapeutic effects improving the dystrophic-
phenotype (S. Bell, personal communication).  
Hypothesis  
DMD is a progressive muscle wasting disease with no cure. HRG was shown to 
alleviate the dystrophic phenotype in mdx mice. HRG has also been shown to activate 
ERK in C2C12 myotubes inducing the gene transcription of many NMJ proteins including 
the dystrophin homolog, utrophin. Although utrophin did not appear to be significantly 
affected by HRG in vivo, ERK involvement in other proteins involved in NMJ function 
would be of interest. AKT has been shown to be important for muscle health and fiber 





target of HRG signaling. Based on these observations, it is hypothesized that HRG 
activation of ERK and AKT and the activation of proteins downstream of AKT and ERK 
might be responsible for NMJ gene induction, improved cell survival, or other effect that 
ameliorated the dystrophic phenotype observed in HRG-treated mdx mice. Specifically, 
AChR clustering and NMJ formation were of interest as they had previously been 
identified as downstream targets of HRG and ERK signaling. This thesis evaluated the 
effects of HRG on muscle biochemically, through cell signaling assays, and histologically, 
by analysis of AChR clustering in vitro and NMJ formation in vivo, to elucidate a 




















Materials and Methods: 
C2C12 cell culture and myotube differentiation 
C2C12 mouse myoblasts were cultured in DMEM (Dulbecco's Modified Eagle 
Medium) high glucose plus GlutaMAX with 1% Pen/Strep and 10% fetal bovine serum 
(normal growth medium) (all from Life Technologies) (McMahon et al., 1994). Cells were 
between 2 and 10 passages before seeding into 6, 12, or 96 well cell culture treated 
plates (Costar) and maintained at ≤50% confluency. To differentiate myoblasts into 
myotubes, cells were grown to 80% confluency and switched to DMEM containing 2% 
horse serum (Invitrogen) for at least 3 days for differentiation and then switched back to 
normal growth medium.                                        
Signaling and cell lysis 
A 71 amino acid rhHRG fragment encoding only the EGF domain was obtained 
from R&D Systems and resuspended in Tris-buffered saline (TBS). Cultured myoblasts or 
myotubes were serum-starved for up to 4 hours and then treated with phosphate-
buffered saline (PBS, vehicle) or HRG up to 1600ng/mL, washed with ice cold PBS, and 
lysed by the addition of a sufficient amount of RIPA buffer (Sigma) containing 
phosphatase and protease inhibitors (Pierce) at various time points. Each condition was 
collected separately and centrifuged. The pellets were discarded and supernatants 
reserved. All samples were then kept on ice for the duration of the experiment or stored 





Total protein concentration of cell supernatants was determined by a BCA 
protein Assay Kit (Pierce). Samples were diluted appropriately with RIPA buffer to 
normalize protein concentrations for all samples per experiment. SDS-PAGE sample 
buffer and reducing agent (NuPAGE, Life Technologies) were added to samples, boiled 
and centrifuged at max speed for 30 seconds. Samples were resolved by SDS-PAGE on 4-
12% Bis-Tris NuPAGE gels (Invitrogen). Gels were transferred to nitrocellulose 
membranes with an iBlot (Invitrogen) and blocked for 45 minutes at room temperature 
with StartBlock (Pierce). Membranes were probed overnight at 4°C with primary 
antibodies, washed, and probed with fluorescent- or HRP-conjugated secondary 
antibodies for 45 minutes. The blots were processed and images acquired on a 
Fluorchem M Imager (Protein Simple). Images were analyzed by band densitometry 
(Alpha View SA).  
Antibodies 
All antibodies used for Western blotting were purchased from Cell Signaling; ERK 
1/2: mouse L34F12, Phospho-ERK: rabbit Y204, AKT: mouse 4074, Phospho-AKt: rabbit 
S473. Secondary antibodies were purchased from Invitrogen: goat anti-mouse alexa 
fluor 546, goat anti-rabbit alexa fluor 430, anti-mouse HRP conjugate, anti-rabbit HRP 
conjugate.  
Electrochemiluminescence (ECL) /MSD (Meso Scale Discovery) detection 
 Differentiated C2C12 myotubes were HRG-treated or vehicle-treated, washed 





assayed using a Meso Scale Discovery electrochemiluminescence (ECL) assay as per the 
manufacturer’s instructions for AKT, ERK1/2, GSK3-β, JNK, p-38, and mTOR1/2.   
Histology and cell staining 
C2C12 cell culture followed the same protocol as mentioned previously with the 
following exception, cells were either plated into fibronectin coated (25µg/mL, 
Invitrogen) 4-well chamber slides (glass or plastic) or 96-well UV-transmissible plates 
(Greiner, cell culture treated). 20, 40, or 60µM Laminin-111 (laminin) (Sigma) was added 
on day 3 of differentiation, at the same time 8ng/mL or 80ng/mL HRG was administered 
for 48-72 hours. Once the HRG-treatment time course was finished, cells were 
incubated with alpha-bungarotoxin (α-btx) conjugated to alexa fluor 555, (5µg/mL, 
Invitrogen) for 1 hour at 37°C, washed with PBS and fixed with 4% paraformaldeyde for 
30 minutes at room temperature or cold methanol for 10 minutes on ice. The cells were 
then washed with PBS and permeabilized with 0.02% Triton X-100 (Sigma) with Hoechst 
to visualize nuclei (Life Technologies). Chamberslides were washed, dried overnight, and 
mounted with Prolong Gold Antifade with DAPI and 96-well plates were washed, 
incubated with Hoechst and left in 150µL of PBS at 4°C until imaged.  
Fluorescent microscopy 
Chamberslides were imaged on a Leica DM4000b fluorescent microscope fitted 
with a DFC 550 CCD camera with 20x and 40x objectives and analyzed with LAS AF 
software. Whole chamberslide images were acquired and stitched together using an 





imaged on an Image Express and processed using Columbus Software (Perkin Elmer) by 
batch analysis of 16 fields per well n≥3 wells per condition. AChR cluster count, cluster 
area determination and intensity were calculated by determining a minimum threshold 
of 70% and identifying clusters through spot detection with area >300nm² and 
<6000nm² and corrected spot intensity >450 and contrast >0.3 similar to Ball, et al. 
(Matthew K. Ball, 2013). Statistical analysis of variance was performed using the 
Students T-test (one-tailed, two sample of unequal variance). 
In-vivo HRG efficacy study 
Three week old mdx and WT 10snJ mice were treated three times a week with 
vehicle (PBS) or 200µg/kg of HRG via intraperitoneal injection: 10 WT + vehicle, 12 mdx 
+ vehicle, and 13 mdx + 200ug/kg HRG. An effort to exacerbate the mild mdx pathology 
was attempted by submitting the mice to 30 minute treadmill exercise twice a week. 
The study continued for 3 months and mice were sacrificed and tissues harvested for 
functional or histological analysis. A time course of HRG-treatments during the animal 






Figure 8: Time course of HRG-treatment in mice 
tissue sectioning and immunohistochemistry  
 Fresh frozen tibialis anterior muscles (TA) from the HRG efficacy study were 
warmed to -20°C overnight. Tissues were placed in a cryostat (LEICA CM 1950) for 20 
minutes to equilibrate temperature. Several 35µm thick longitudinal sections were 
transferred onto positively charged slides per condition. Tissues were fixed in 4% 
paraformaldehyde for 30 minutes followed by three washes with PBS for 5 minutes 
each. Tissues were subjected to 0.3M glycine to reduce autofluoresence, blocked and 
permeabilized for 45 minutes with 0.02% Triton X-100 and 0.5% BSA (Sigma), and 
followed by a series of washes with PBS (Life Technologies). Tissues were stained 
overnight with primary anti-neurofilament (NF) antibody (Developmental Studies 
Hybridoma Bank – University of Iowa) at 4°C. Slides were washed and then incubated 
with alexa fluor 488-conjugated secondary antibody (Life Techniologies) and alexa fluor 





blocking buffer. The samples were dried overnight and mounted with Prolong Gold 
Antifade with DAPI (Invitrogen).  
Epi-fluorescence and confocal microscopy of tissue sections 
 Sections were initially imaged & analyzed with a Nikon E800 Upright Epi-
fluorescent microscope. Around 48 NMJs were imaged per mouse (n=7) for each 
condition through fluorescent microscopy. Confocal images were captured with a 40x oil 
objective and 20-24 Z-stacks, each stack ~1-1.7µm on a Carl Zeiss LSM780 confocal 
microscope. Around 6 NMJs per mouse (n=4) for each condition were imaged and 
analyzed by confocal microscopy. Confocal raw data images were extracted with Imaris 








HRG signaling in myoblasts and myotubes 
The effect of HRG to ameliorate the dystrophic phenotype in mdx mice through 
the up-regulation of utrophin has not been consistently shown as an HRG mechanism of 
action (Krag et al. 2004 & S. Bell, personal communication). To help identify the 
mechanism of action by which HRG preserves muscle function, HRG signaling was 
investigated. It had previously been shown that HRG activates ERK in skeletal muscle 
and induces gene expression of NMJ proteins (Altiok, Altiok, & Changeux, 1997; Fromm 
& Burden, 2001; Handschin et al., 2007; Tansey et al., 1996). To confirm previous 
findings and to establish experimental protocols, ERK activation by HRG was examined. 
Mouse C2C12 myoblasts and differentiated myotubes were serum-starved and 
then treated with varying concentrations of HRG for various times. Activated signaling 
proteins were analyzed by Western blot with phospho-specific antibodies. Activation 
was normalized by the ratio of phosphorylated to non-phosphorylated protein signal. 
HRG activation of ERK in undifferentiated myoblasts is shown in Figure 9. HRG activation 






Figure 9: Activation of ERK in undifferentiated myoblasts  
Western blot and densitometry analysis at 10 minutes showing ERK activation with 200 and 
800ng/mL HRG in undifferentiated myoblasts. Each condition was performed in duplicate. These 






Figure 10: HRG activation of ERK in differentiated myotubes  
Differentiated myotubes were treated with 0, 50, 100, 400, 800 & 1600ng/mL HRG for 
15 minutes. Lysates were analyzed by Western blot and densitometry analysis. Each 
condition was performed in duplicate. These data are representative of 3 experiments. 
 
The HRG-mediated activation of ERK confirmed previous findings of ERK 
activation in C2C12 cells. Since ERK activation occurred in undifferentiated myoblasts 
and differentiated myotubes, a direct effect, specific to differentiated muscle myotubes, 
could not be linked to ERK activation following HRG treatment. Other MAP Kinase 
pathways, JNK (c-Jun N-terminal kinase) and p38 were examined. JNK and p38 are 
crucial for cell survival and regulate cell proliferation (Bernet et al., 2014; Sakamoto & 





experiment, ERK, JNK and p38 protein and their phospho-protein isoforms were assayed 
in a single ECLA experiment (n=2 biological replicates per experiment, n=6 experimental 
replicates). The results confirmed a HRG dose dependent activation of ERK, peaking at 
10 minutes (Figure 11), but revealed no activation of JNK (Figure 12) or p38 (Figure 13) 
in differentiated C2C12 myotubes.. 
 
Figure 11: HRG dose dependent ERK activation  
ECLA showing that HRG activation of ERK peaks by 10 minutes at 40 and 200ng/mL HRG. 
Data are the average of duplicates and representative of 6 independent experiments. 
 
 
Figure 12: HRG does not activate JNK 
ECLA showing that HRG does not appear to activate JNK between 5 and 30 minutes at 8, 







Figure 13: HRG does not activate p38 
ECLA showing that HRG does not appear to activate p38 between 5 and 30 minutes at 8, 




 AKT has been shown to be important in muscle, and HRG activation of AKT has 
previously been demonstrated in non-muscle cells in vitro. However, it is not clear if 
HRG activation of AKT in dystrophic muscle would be beneficial. AKT is linked to muscle 
cell survival, differentiation through the stimulation of growth factors, fiber type 
switching, and glucose metabolism (Blaauw et al., 2009; Blaauw et al., 2008; Schiaffino 
& Mammucari, 2011). To test the activation of AKT in muscle-derived cells, C2C12 
myoblasts and myotubes were treated with HRG as in the MAP kinase experiments 
above. Dose-dependent activation of AKT was detected following HRG-treatment. 
However, unlike ERK, AKT was only activated in differentiated myotubes (Figure 15) and 
not myoblasts (Figure 14). This myotube specific effect could mean that downstream 
events from AKT activation might contribute to the prevention of muscle dystrophy 





       
 
Figure 14: Activation of AKT in undifferentiated C2C12 myoblasts 
Myoblasts were treated with 0, 50, 100, 400, 800 & 1600ng/mL HRG for 10 minutes. 
Lysates were analyzed by Western blot and densitometry analysis. Each condition was 
performed in duplicate. These data are representative of 3 experiments. 
     
Figure 15: Activation of AKT in differentiated C2C12 myotubes 
Differentiated myotubes were treated with 0, 50, 100, 400, 800 & 1600ng/mL HRG for 
10 minutes. Lysates were analyzed by Western blot and densitometry analysis. Each 







 As AKT activation was differentially activated in C2C12 myotubes, downstream 
signaling might be important for potential AKT-mediated benefits. Downstream 
pathways of AKT were investigated to explore HRG signaling. GSK-3β, a substrate of AKT, 
was investigated because of its involvement in cell fate, development, and glycogen 
synthesis (Wojtaszewski, Nielsen, Kiens, & Richter, 2001). It was previously shown that 
the activation of p70s6k from AKT was linked to the alleviation of muscular dystrophy by 
promoting muscle cell survival (Boppart, Burkin, & Kaufman, 2011). In order to simplify 
analysis of downstream AKT signaling, AKT, GSK-3β and p70s6K protein and phospho-
protein isoforms were assayed in a single ECLA experiment (n=2 biological replicates per 
experiment, n=6 experimental replicates). While these experiments confirmed 
activation of AKT between 5 and 30 minutes (Figure 16), it was observed that HRG did 
not activate either GSK-3β (Figure 17) or p70s6K (Figure 18) up to 90 minutes following 
HRG treatment (data not shown). Although the GSK-3β data at 5 and 10 minutes 
suggested there might have been activation, in six additional experiments, this 
observation was never repeated.  
 
Figure 16:  HRG dose activation of AKT in C2C12 myotubes 





HRG, but remains active for at least 30 minutes. Data are the average of duplicates and 




Figure 17: HRG does not activate GSK-3β 
ECLA showing that HRG does not appear to activate GSK-3β between 5 and 90 minutes 





Figure 18: HRG does not activate p-70s6k 
ECLA showing that HRG does not appear to activate p70s6k between 5 and 30 minutes 
at 8, 40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6 
independent experiments. 
 
mTOR, another protein downstream of AKT and linked to the prevention of 
muscle atrophy and mitochondrial health, was investigated (Bodine et al., 2001). mTOR 
showed no activation following HRG treatments up to 90 minutes in an ECLA (Figure 19), 





unexpected as mTOR is responsible for cell survival and is a common target of AKT 
signaling (Bodine et al., 2001). It is important to keep in mind that the signaling 
experiments were performed in C2C12 myotubes in vitro, not muscle tissue in vivo. The 
C2C12 myotubes may be an incomplete model for signaling in muscle.  
 
Figure 19: HRG does not activate mTOR 
ECLA showing that HRG does not appear to activate mTOR between 10 and 90 minutes 
at 8, 40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6 
independent experiments. 
  
HRG effects on AChR clusters in C2C12 myotubes  
The activation of ERK by HRG has been shown to induce the expression of 
several NMJ proteins including AChR (Handschin et al., 2007). It has also been shown 
that laminin induces AChR clustering in differentiated C2C12 myotubes, and dystrophin-
deficiency contributes to the loss of AChR cluster organization (Personius & Sawyer, 
2005; Sugiyama, Glass, Yancopoulos, & Hall, 1997). The effects of HRG signaling on 
laminin-induced AChR clustering and morphology in differentiated C2C12 myotubes 
were examined by histological analysis. AChR clustering occurred spontaneously in 
differentiated myotubes (Figure 20A).  The addition of laminin induced or accelerated 





HRG-treatment reduced AChR clustering (Figure 20C). C2C12 myotubes, which were 
treated with HRG and laminin at the same time, appeared to show an effect on the 
spatial organization of AChR clusters. It was observed that HRG appeared to influence 
the location of laminin-induced AChR clusters with some clusters having a central 
localization (Figure 20D) compared to only being on an edge, whether a cell-cell or cell-
matrix interaction (Figure 20B). This phenomenon indicated HRG-treated Laminin 
induced AChR clusters might be more matrix-cell independent. In HRG-treated 
myotubes, the α-btx stain appeared dimmer in laminin-induced clusters (Figure 20D) 
while having a brighter and more diffuse membrane staining in the absence of laminin 
(Figure 20C), suggesting a greater dispersal of AChRs. These results are similar to 







Figure 20: HRG modulated AChR clustering in differentiated C2C12 myotubes 
Epi-fluorescence microscopy of a-btx stained C2C12 differentiated myotubes on 
fibronectin-coated slides.  No Laminin-1 or HRG added (A), 60nM Laminin-1 (B), 8ng/mL 
HRG induction (C) (D) 60nM Laminin-1 and 8ng/mL HRG induction (D). Note: Blue arrows 
represent AChR clustering, white arrors shows AChRs dispersed throughout myotubes 
or centralized cluster.  
 
To quantitate the observations made subjectively on AChR clustering in C2C12 
myotubes plated on fibronectin-coated slides, C2C12 cells were plated onto 96 well UV-





24, 48, 72 and 96 hours with the number of wells indicated (n): No laminin+no HRG 
(n=12); no laminin+8ng/mL HRG (n=6); no laminin+80ng/mL HRG (n=6); 20nM 
laminin+no HRG (n=6); 40nM laminin+no HRG (n=6); 60nM laminin+no HRG (n=6); 20nM 
laminin+8ng/mL HRG (n=3); 40nM laminin+8ng/mL HRG (n=3); 60nM laminin+8ng/mL 
HRG (n=3); 20nM laminin+80ng/mL HRG (n=3); 40nM laminin+80ng/mL HRG (n=3); 
60nM laminin+80ng/mL HRG (n=3).  Sixteen fields from each well were imaged by an 
Image Express (Molecular Devices) for a minimum of 48 images per condition. Each field 
contained 2-12 myotubes or fractions of myotubes.  The images were analyzed in batch 
using Columbus software (Perkin Elmer) to identify clusters as detailed in Materials and 
Methods. AChR clusters were identified, counted, and the cluster area and intensity 
determined. The intensity value is relative to the concentration of AChRs found in 
clusters while the area is indicative of cluster size. At 24 hours following HRG-
treatments, there was no significant difference in the trending of AChR clustering (data 
not shown). However, HRG had a dose-dependent effect on the laminin-induced AChR 
clusters on cluster number, total cluster intensity (Figure 21A) and mean cluster area 
(Figure 21B) at 48 hours. The addition of 80ng/mL HRG reduced the total number of 
20nM and 60nM laminin-induced clusters/well by 34% (p<0.02) and 23% (p=0.05), 
respectively. While HRG treatment reduced the total cluster intensity of laminin-induced 
clusters, only at 80ng/mL HRG and 60nM laminin-1 was the effect statistically significant 
(p<0.01).  Similarly, HRG significantly reduced the mean cluster size (area) at 80ng/mL 
for the 60nM laminin-induced clusters (p<0.01).  AChR clustering was also examined at 





observed. The dose-dependent HRG-effects appeared to diminish by 72 hours. No 
attempt was made to determine localization of AChR clusters as that appeared to be 
beyond the capacity of the algorithm for the staining protocol that was performed. 
 
Figure 21: AChR clustering after a 48 hour HRG treatment  
AChR clustering count in differentiated C2C12 myotubes on the fifth day of 
differentiation with a 48 hour HRG treatment of 8 and 80ng/mL HRG on spontaneous 
and laminin-induced AChR cluster formation showing (A) sum cluster intensity/well and 







 Figure 22: AChR clustering after a 72 hour HRG treatment 
 AChR clustering count in differentiated C2C12 myotubes on the sixth day of 
differentiation with a 72 hour HRG treatment of 8 and 80ng/mL HRG showing (A) sum 
cluster intensity/well and (B) area/AChr cluster. Error bars depict standard deviation of 
well averages. 
Effects of HRG on NMJ formation in vivo  
Our observation of HRG activation of ERK, its documented downstream effects 
on NMJ gene transcription, and our observation of AChR cluster reorganization led us to 
examine whether HRG might affect NMJ morphology in the mdx mouse.  NMJs, which 
are shown to be defective in mdx mice (Figure 6), might benefit from ERK and/or AKT 
signaling. In order to understand the effect HRG has on NMJ formation, the TA muscles 
from vehicle and HRG-treated mdx mice and vehicle-treated wild type (WT) mice were 
examined by staining with alexa fluor 555-conjugated α-btx, which stains the AChR on 





vast majority of the WT NMJs examined in this study were comparable to those found in 
the scientific literature showing a continuous pretzel-like NMJ (Figure 22A and 23A) 
(Arnold et al., 2014; Bolliger et al., 2010). The mdx mouse had discontinuous NMJ 
formation, which is commonly referred to in the literature as Island-like or bouton 
formation. The NMJ islands in HRG-treated mdx tissue appear to be more conjoined 
(Figure 23C and 24) when compared to the random, bouton mdx NMJs (Figure 23B and 
24). HRG treatment did not completely restore the mdx NMJ phenotype to WT, but HRG 
treatment did show a partial restoration of NMJ morphology.  
       
Figure 23: General NMJ morphology 
WT 10snJ mice show healthy pretzel-like NMJs (A) while mdx mice show a 
discontinuous,  island-like NMJs (B), and 200ug/kg HRG-treated mdx mice show a 
partially restored morphology (C).  
 
 To further understand any effects HRG might have beyond changes in overall 
NMJ morphology, the interaction between the nerve terminal and muscle were 
analyzed by co-staining with an antibody to neurofilament (NF) protein found in the 





Through Epi-fluorescence microscopy, it was observed that in some NMJs the axons of 
nerve terminals had higher integration throughout the NMJ when mdx mice were 
treated with HRG than compared to the vehicle-treated mdx mice (data not shown) and 
was confirmed through confocal microscopy (Figure 24A). Confocal microscopy was 
used to determine a more precise location of axonal and AChR interactions. HRG-
treated tissues showed a higher nerve terminal integration with AChR throughout the 
NMJ, as though the nerve was trying to compensate for the NMJ malformation by 
reaching out to each island when compared to the vehicle-treated mdx mouse muscle, 






Figure 24: HRG effects on AChR and axonal interactions  
NMJs are shown in red and the axon (nerve terminal) is shown in green. Confocal 
microscopy showing location of axonal and NMJ interaction in WT (Left), mdx + vehicle 
(middle), and 200µg/kg HRG-treated (Right) NMJs. HRG effects on AChR and axonal 
interactions showing increased integration (A), however, HRG effects on NMJ and 
axonal interactions are not consistent (B). Data are representative of 6 NMJs analyzed 






It appeared that HRG-treated mice showed a higher integration of nerve 
terminals throughout the NMJ compared to the vehicle. Yet, the effect seen from HRG-
treatments was not consistent among all NMJs (24B), possibly due to incomplete 
biodistribution of HRG. This data led us to the possible conclusion that HRG might 
modify NMJ formation and possibly influence nerve terminal migration to better adapt 
to signaling in mdx NMJs and improve muscle function through increased excitation 
contraction coupling.  
Results summary 
In summary, through in vitro and in vivo experiments, mechanisms of action for 
HRG-mediated effects on muscle were examined. HRG signaling in vitro provided 
confirmation of ERK activation in undifferentiated myoblasts and differentiated 
myotubes, whereas AKT activation was observed only in differentiated myotubes. There 
was no clear evidence of JNK, p38, GSK-3β, p70s6K or mTOR activation. Due to HRG 
activation of ERK and NMJ gene up-regulation as a result of ERK signaling, AChR 
clustering in differentiated C2C12 myotubes was investigated and found to have a dose-
dependent decrease in AChR cluster area and intensity. NMJ morphology was examined 
in vivo following the administration of HRG to mdx mice. NMJs in mdx mice treated with 
HRG showed a partial restoration in NMJ morphology. Co-staining AChRs of HRG-treated 
and non-treated mdx mice with a NF antibody provided evidence that HRG increased 
NMJ integration between the nerve terminal and AChRs, which could lead to improved 







A downstream signaling mechanism has not yet been determined 
              The HRG signaling pathway in muscle has not been completely elucidated. In 
differentiated C2C12 myotubes, HRG activates AKT and ERK, but surprisingly does not 
activate mTOR, JNK, p-38, p70s6k, or GSK-3β, which are downstream of AKT and ERK or 
represent parallel pathways. Downstream signaling of ERK in C2C12 myoblasts and 
myotubes have been thoroughly studied and, for the most part, point to the induction 
of AChR, utrophin and many other NMJ-associated genes. The results presented here 
indicate that the ERK activation observed in C2C12 cells may translate to the 
reorganization of laminin-induced AChR clusters in vitro and the improvement of NMJ 
formation in vivo. Although the result could be predicted based on literature, this study 
is the first to make the direct observation of HRG affecting the NMJ of mdx mice in vivo. 
Although AKT is activated in vitro in C2C12 myotubes, the effects of this activation were 
not determined in this study.  
 HRG activation of AKT did not lead to the activation of GSK-3β, mTOR, or 
p70s6k, downstream mediators of AKT signaling. This result was surprising and indicates 
that there may be a separate pathway activated by HRG through AKT. More likely, it 
could mean that C2C12 cells are not a surrogate for muscle when examining AKT 
signaling. AKT signaling is responsible for fiber-type switching, muscle fiber hypertrophy 
and decreased muscle apoptosis. However, it was not possible to examine these effects 
in vitro. These responses to AKT activation could be mediated by mTOR, which is 





was surprising to find HRG did not activate mTOR (Bodine et al., 2001). HRG activation 
of AKT was specific to myotubes and might point to a different outcome for more 
mature muscle upon the administration of HRG. Due to the limitations in the C2C12 cell 
culture model, investigation of AKT and mTOR signaling in vivo may yield different 
results.  
HRG decreases AChR clustering in C2C12 differentiated myotubes  
ERK activation has been associated with NMJ-associated gene expression. As 
HRG activated ERK, it might be expected that an effect on AChR clusters would be 
observed. What was surprising was the nature of the HRG effects. One would expect 
that HRG-treatments might increase AChR clusters as HRG treatment has been shown to 
increase total AChR protein. What was observed in this study, however, was not an 
increase in AChR clusters, but a decrease in number, area, and intensity of the Laminin-
induced AChR clusters at 48 hours. There was an increase in overall clusters in the 72 
hour time point compared to the 48 hour time point. However, the HRG effects seemed 
to diminish by 72 hours. Interestingly, there did not seem to be a trend in AChR clusters 
treated with only laminin. 
 
When myotubes were not subjected to HRG or laminin treatments, AChR 
clustering is spontaneous as shown in Figure 20A. AChRs in myotubes treated with HRG 
(Figure 20C) appeared to be more dispersed throughout the membrane when compared 
to treatment of cells with Laminin-1 (Figure 20B). Further investigation could focus on 





throughout the myotubes when compared to just the Laminin-1 treatment) observed in 
cell culture translates to the partial repair in NMJs as seen in vivo (Figure 23 and 24). 
HRG modifies NMJ morphology to improve axonal integration 
It was observed that AChR clusters not only decrease in the presence of HRG, but 
clusters were not restricted to the edges of myotubes suggesting enhanced remodeling, 
dispersion, and/or plasticity resulting from HRG signaling; this finding led to the 
investigation of HRG-effects on NMJ formation. HRG partially repaired NMJ morphology, 
reducing the bouton formation and increasing contiguous α-btx staining. It is unclear 
whether this observation is a direct result of ERK activation, but many studies have 
indicated a role for ERK activation by HRG in the control of NMJ gene regulation and 
would support an effect mediated through ERK. It would be interesting to evaluate 
correlations between ERK activation and partial repair of NMJ following HRG-
treatments. Although HRG may appear to modify NMJ formation and increase axonal 
and NMJ integration, these observations are not consistent between all NMJs or mice. 
As some mice responded better to HRG treatments (S. Bell, personal communication), 
this could be due to the variability of the mdx model, bioavailability of HRG to all muscle 
tissue or a combination of both factors. Further analysis by BioMarin of other tissues 







It has been observed that HRG can ameliorate the dystrophic phenotype in mdx 
mice.  However, the mechanism of action of HRG had not been identified.  In fact the 
proposed mechanism of utrophin induction was not reproduced by BioMarin 
researchers.  The goal of this thesis was to explore and/or determine alternative 
mechanisms of action that would explain the benefits of HRG treatment on dystrophic 
muscle.  Although AKT activation in C2C12 cells possibly created more questions than 
were answered, the reproducible activation of ERK and the body of literature linking ERK 
to the regulation of NMJ genes supported the examination of HRG effects on AChR 
clustering and NMJ formation.  It had previously been observed that AChR total protein 
increases upon HRG treatment. However, an increase in AChR clusters was not 
observed. Just the opposite was observed:  fewer clusters, less area per cluster and at a 
lower intensity indicating fewer AChR/cluster.  Another observation was that AChR 
clusters were not restricted to the edges of tubes, suggesting enhanced remodeling or 
plasticity was induced by HRG treatment.  When NMJs were analyzed in TA muscle from 
HRG-treated mdx mice, an improvement in NMJ morphology and neurofilament 
interaction was observed, supporting a potential role of HRG in promoting NMJ 
plasticity and repair of defective mdx NMJ.  This improved NMJ structure may improve 
excitation contraction coupling to restore muscle function or prevent muscle damage. 
Although not definitive, this thesis goes a long way towards suggesting a novel 
mechanism of action for HRG in the amelioration of the dystrophic phenotype 





NMJ function. The evidence reported here supports a role for HRG involvement in NMJ 
plasticity and repair to improve excitation contraction coupling in mdx mice as a 
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